GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Turnstone Biologics
The shares of Turnstone Biologics, an oncology company developing oncolytic viruses, reflect the potential of its scientific platform. The trajectory of its price after the IPO will depend on success in clinical trials and partnerships with major pharmaceutical companies.
Share prices of companies in the market segment - Oncology immuno-therapy
Turnstone Biologics is an oncology company developing immunotherapies based on oncolytic viruses and vaccines for the treatment of solid tumors. We've classified it in the "Immuno-Oncology" category. The chart below shows how investors view this cutting-edge, yet risky, biotech sector.
Broad Market Index - GURU.Markets
Turnstone Biologics is an oncology company developing immunotherapies based on oncolytic viruses and T-cell therapy. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Turnstone shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TSBX - Daily change in the company's share price Turnstone Biologics
For Turnstone Biologics Corp., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Turnstone Biologics is a biopharmaceutical company developing oncolytic viruses and tumor-infiltrating lymphocyte (TIL) therapies for the treatment of cancer. Immuno-oncology is a highly volatile sector. The chart below reflects average fluctuations in this industry, providing context for evaluating TSBX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Turnstone Biologics is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Turnstone Biologics
For Turnstone Biologics, year-over-year performance is a story about the development of its cancer immunotherapy platform. Its 12-month market cap depends entirely on clinical trial data for its oncolytic viruses and TIL-based cell therapy. Success in either area could be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
As an early-stage biotech, Turnstone is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news of clinical trials of its oncolytic virotherapy. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Turnstone Biologics is an immuno-oncology company whose stock is a bet on a new generation of cancer drugs. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its platform. It's a high-risk play where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Turnstone Biologics
Turnstone is an oncology company developing oncolytic viruses. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the viability of its platform are the main driver.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biotech company developing two types of cancer immunotherapies: oncolytic viruses and TIL-based cell therapy. The graph below illustrates the dynamics of the biotech sector, where the search for combinations of various immunotherapies is a promising area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Turnstone Biologics is a biotech company developing oncolytic viruses and cell therapies for cancer treatment. Its shares represent a venture bet on the success of breakthrough scientific approaches. Their performance is entirely dependent on news from the laboratory and the clinic.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Turnstone Biologics
Turnstone, an oncology company developing oncolytic viruses, shares reflect progress in this field weekly. The stock price responds to clinical trial data demonstrating whether its "smart" viruses can effectively destroy cancer cells.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Turnstone Biologics develops oncolytic viruses and cell therapies for cancer treatment. This chart compares its volatile, data-driven performance with the immuno-oncology sector and helps us understand how much investors believe in its dual-platform approach to fighting tumors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Turnstone Biologics is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Turnstone is operating in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
TSBX - Market capitalization of the company Turnstone Biologics
Turnstone's market capitalization tells the story of a biotech company developing oncolytic viruses and cell therapies. Its speculative performance reflects investors' assessment of its scientific platform and early clinical trial data. Its trajectory is a narrative of hope for a new generation of cancer treatments.
TSBX - Share of the company's market capitalization Turnstone Biologics within the market segment - Oncology immuno-therapy
Turnstone Biologics is an oncology company developing a new generation of immunotherapy. Its small share of the biotech sector's market capitalization reflects its early stage of development. The chart shows how its share changes as data from clinical trials of its viral platform is released.
Market capitalization of the market segment - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biotech company developing viral immunotherapy for cancer treatment. The chart below shows the overall market capitalization of the oncology sector. Its dynamics reflect the intense interest in new approaches that can "awaken" the immune system to fight tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
Turnstone Biologics is a biotech company developing oncolytic viruses and cell therapies. Its market cap reflects the success of its multifaceted approach to immuno-oncology. Its performance on the overall chart reflects how science is attacking cancer from multiple angles.
Book value capitalization of the company, segment and market as a whole
TSBX - Book value capitalization of the company Turnstone Biologics
Turnstone Biologics' balance sheet consists of its capital and patents for its oncolytic virus and vaccine platform for cancer treatment. This is the tangible, scientific foundation for a new approach in immuno-oncology. How has this innovative biotech asset changed during clinical trials? The chart below shows its dynamics.
TSBX - Share of the company's book capitalization Turnstone Biologics within the market segment - Oncology immuno-therapy
Turnstone Biologics develops oncolytic viruses and cancer vaccines. The chart shows the proportion of its unique R&D and manufacturing assets, reflecting the physical foundation of its innovative immuno-oncology platform.
Market segment balance sheet capitalization - Oncology immuno-therapy
Turnstone, a biopharmaceutical company developing oncolytic viruses, has a capital-intensive R&D business. This requires the ownership of cutting-edge laboratories. The BCap_Seg chart for the biotech sector shows that breakthrough research requires a robust scientific infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Turnstone's balance sheet is its viral cancer immunotherapy platform. The company's assets are its intellectual capital, patents, and, potentially, virus production facilities. The chart below shows how this pioneer in oncolytic viruses stacks up in terms of assets within the biotech world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Turnstone Biologics
Turnstone Biologics is a company developing oncolytic viruses and cell therapies for cancer treatment. Its balance sheet is its unique scientific platform. Its market capitalization reflects its belief in its innovative "one-two punch" approach to tumors. The chart reflects high expectations for a new class of oncology drugs.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing viral immunotherapy for cancer treatment. Its market valuation in the chart is based solely on the potential of this innovative scientific approach, not on its current tangible assets, reflecting the high risks and investor expectations.
Market to book capitalization ratio for the market as a whole
Turnstone Biologics is an oncology company developing viral therapies. Its value is almost entirely derived from investor expectations regarding its scientific platform. This chart demonstrates how high the premium for breakthrough but high-risk approaches to cancer treatment is compared to the market average.
Debts of the company, segment and market as a whole
TSBX - Company debts Turnstone Biologics
Turnstone Biologics, an oncology company developing viral and cell therapies, uses capital to fund its innovative and complex clinical programs. This chart shows how the company is raising significant funds to advance its promising, but high-risk, approaches to cancer treatment.
Market segment debts - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biotech developing oncolytic viruses and cell therapies. This chart demonstrates that the company, like its peers in the sector, relies solely on equity capital to fund its cutting-edge and risky research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Turnstone Biologics
Turnstone Biologics is a biotech company developing a new class of oncolytic viruses for cancer treatment. This is a cutting-edge but risky field. This chart shows how much the company relies on debt to finance its expensive clinical trials. It is a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing a new class of oncolytic viruses and vaccines for cancer treatment. This is a cutting-edge approach in immuno-oncology. The chart shows how aggressively the sector uses debt for R&D, providing context for assessing how Turnstone finances its risky but promising programs.
Debt to book value of all companies in the market
Turnstone Biologics, an oncology company developing viral immunotherapy, is at the forefront of science, requiring massive investments in R&D. This chart, reflecting the overall market debt burden, helps assess the company's financial risk. It shows how the company is funding its breakthrough, yet high-risk, clinical trials.
P/E of the company, segment and market as a whole
P/E - Turnstone Biologics
Turnstone Biologics is a clinical-stage biopharmaceutical company developing next-generation oncolytic viruses and vaccines for cancer treatment. This chart shows how investors value its immunotherapy platform. This valuation is based on the potential of its approaches to stimulating the immune system to fight tumors.
P/E of the market segment - Oncology immuno-therapy
This chart illustrates the average P/E ratio for biotech companies. For Turnstone Biologics, which works in the field of viral immunotherapy for cancer, it serves as a backdrop. It shows the overall level of investor confidence in this cutting-edge field of oncology, providing context for valuing Turnstone and its scientific platform.
P/E of the market as a whole
Turnstone Biologics is a biotech company developing oncolytic viruses and cell therapies for cancer treatment. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Turnstone's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Turnstone Biologics
This chart for Turnstone Biologics Corp., a company developing oncolytic viruses and cell therapies for cancer, shows market expectations for its clinical programs. It reflects investor confidence in the synergy of its approaches to combating solid tumors.
%20P%2FE%20Turnstone%20Biologics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Turnstone-Biologics&v=1772635354383 "Chart of the company's future (projected) P/E Turnstone Biologics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biopharmaceutical company developing a new generation of oncolytic viruses and vaccines for cancer treatment. This chart shows forecasts for the oncology sector. This helps compare how the market views Turnstone's innovative, yet risky, approach to immuno-oncology and the potential of its platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772635354411 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Turnstone Biologics Corp. is a biotech company developing viral immunotherapy for cancer. This is an innovative approach in oncology. The company's valuation is a bet on future success. This chart shows how willing investors are to fund such high-risk, yet potentially breakthrough, scientific approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635354526 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Turnstone Biologics
Turnstone Biologics is a clinical-stage oncology company developing viral immunotherapies and tumor-infiltrating lymphocyte (TIL)-based therapies. Its financial results represent R&D losses. This chart shows the cost of developing cutting-edge and complex approaches to cancer treatment.
Profit of companies in the market segment - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing next-generation cancer immunotherapies, including oncolytic viruses and tumor-infiltrating lymphocyte (TIL)-based therapies. This sector profitability chart illustrates how science is pursuing multifaceted approaches to fighting cancer. Their goal is to attack tumors from multiple angles to overcome resistance.
Overall market profit
Turnstone Biologics is a biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. This is a cutting-edge approach in immuno-oncology. Funding for such innovative but risky research depends on investor appetite, which typically rises during periods of rising corporate profits, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Turnstone Biologics
Turnstone Biologics is a biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. Its goal is to stimulate the immune system to fight tumors. This chart reflects analysts' speculative expectations for the success of its innovative platforms in clinical trials.
%20profit%20of%20the%20company%20Turnstone%20Biologics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Turnstone-Biologics&v=1772635354642 "Graph of future (projected) profit of the company Turnstone Biologics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. Its future depends on the success of its innovative approaches. This chart for the oncology sector reflects the overall investor interest in immunotherapy and their willingness to fund risky but potentially breakthrough projects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772635354663 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Turnstone Biologics is developing viral immunotherapy for cancer. This is cutting-edge science, requiring significant investment. This graph, reflecting general economic expectations, influences investor willingness to invest in long-term, high-risk, but potentially breakthrough biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635354685 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Turnstone Biologics
Turnstone Biologics is a biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. In the absence of revenue, this chart is crucial. It shows how investors view its innovative scientific platform and future revenue potential, betting on a breakthrough in immuno-oncology.
P/S market segment - Oncology immuno-therapy
Turnstone Biologics is developing a new class of oncolytic viruses and vaccines for cancer treatment. The company's valuation is based on the future potential of its innovative immunotherapeutic platform. This chart, which reflects the average biotech valuation, helps us understand how high investor expectations are for Turnstone's scientific approach and clinical programs.
P/S of the market as a whole
Turnstone Biologics is a biotech company developing a new generation of oncolytic viruses and cancer vaccines to stimulate the immune system. This chart, which reflects revenue estimates for real businesses, highlights that Turnstone's valuation is a bet on its innovative approach to cancer immunotherapy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Turnstone Biologics
Turnstone Biologics is a clinical-stage biotech company developing oncolytic viruses and vaccines for the treatment of solid tumors. This is a cutting-edge approach in immuno-oncology. This chart reflects investor hopes that its scientific platform will prove effective in the fight against difficult-to-treat cancers.
%20P%2FS%20Turnstone%20Biologics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Turnstone-Biologics&v=1772635354777 "The graph of the company's future (projected) P/S Turnstone Biologics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Turnstone Biologics Corp. is a clinical-stage biopharmaceutical company developing a new class of oncolytic viruses and vaccines for the treatment of cancer. This chart reflects average revenue expectations in the immuno-oncology sector. It provides insight into the market's appreciation for Turnstone's innovative approaches to fighting cancer.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772635354785 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Turnstone Biologics is a biopharmaceutical company developing a new generation of oncolytic viruses and vaccines for cancer treatment. This chart shows investor expectations for revenue growth. The company's innovative approaches to immunotherapy fuel hopes for more effective treatments for solid tumors.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635354810 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Turnstone Biologics
This chart shows the revenue of Turnstone Biologics, a clinical-stage biopharmaceutical company developing next-generation oncolytic viruses and cancer vaccines. Its revenue is generated through payments from strategic partnerships, reflecting research progress rather than sales.
Sales of companies in the market segment - Oncology immuno-therapy
Turnstone Biologics is an oncology company developing a new class of viruses that selectively attack cancer cells, as well as tumor vaccines. This chart illustrates the growth of the immuno-oncology market. The company's innovative platforms could lead to breakthrough therapies that utilize both viruses and the immune system to fight cancer.
Overall market sales
Turnstone Biologics is a biotech company developing oncolytic viruses and cell therapies for cancer treatment. Its development depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Turnstone Biologics
Turnstone Biologics is a biotechnology company developing next-generation cancer immunotherapies, including tumor-infiltrating lymphocyte (TIL)-based therapies. Future revenue is dependent on the success of its clinical programs. The schedule reflects confidence in its R&D.
%20sales%20of%20the%20company%20Turnstone%20Biologics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Turnstone-Biologics&v=1772635354849 "Schedule of future (projected) sales of the company Turnstone Biologics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. Its approach utilizes viruses to destroy tumors and stimulate the immune system. This chart shows the forecast for the entire immuno-oncology market, where Turnstone is at the forefront of scientific advancement.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772635354859 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Turnstone Biologics is a clinical-stage biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. Its valuation is dependent on the success of clinical trials. This schedule, reflecting sentiment in the biotech sector, impacts the company's ability to attract funding to advance its innovative immunotherapeutic approaches.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635354880 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Turnstone Biologics
Turnstone Biologics is a biotech company developing a new generation of oncolytic viruses and vaccines for cancer treatment. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in creating a "one-two punch" against tumors, combining direct cancer cell destruction with immune system activation.
Market segment marginality - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biotechnology company developing next-generation oncolytic viruses and vaccines for cancer treatment. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the potential of their innovative immunotherapeutic platforms.
Market marginality as a whole
Turnstone Biologics is a biotech company developing a new class of cancer immunotherapy—oncolytic viruses and virus-based vaccines that stimulate the immune system to attack tumors. This overall profitability curve is irrelevant to them. Their future depends solely on the success of their innovative scientific platform and the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Turnstone Biologics
Turnstone Biologics is a biotech company developing viral immunotherapies for cancer treatment. Its team consists of scientists and clinical development specialists. The growth in this chart reflects the progress of its innovative platform and the advancement of its candidates into clinical trials.
Share of the company's employees Turnstone Biologics within the market segment - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing next-generation cancer immunotherapies, including tumor-infiltrating lymphocyte (TIL) therapy. This chart reflects its research-intensive nature. It shows the size of the team working to address the complex manufacturing and clinical challenges associated with this personalized treatment approach.
Number of employees in the market segment - Oncology immuno-therapy
Turnstone Biologics Corp. is a clinical-stage biopharmaceutical company developing a new generation of cancer immunotherapies based on oncolytic viruses. This chart shows the dynamics of employment in the cutting-edge field of oncology. The growing number of scientists here reflects progress in clinical trials and the potential to create a powerful new tool in the fight against solid tumors.
Number of employees in the market as a whole
Turnstone Biologics is a biotech company developing oncolytic viruses and cell therapies for cancer treatment. Its cutting-edge research requires significant funding. Overall economic stability, reflected in this chart, influences investor willingness to invest in high-risk but breakthrough oncology platforms.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Turnstone Biologics (TSBX)
Turnstone Biologics is a biotech company developing oncolytic viruses and cell-based therapies (TILs) for cancer treatment. It's an R&D company. The chart shows that its market value is a valuation of its scientific platform. The market capitalization per employee (scientist) is high, reflecting investors' faith in the breakthrough potential of their immunotherapy approaches.
%20of%20the%20company%20Turnstone%20Biologics%20(TSBX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Turnstone-Biologics-TSBX&v=1772635355080 "Chart of market capitalization per employee (in thousands of dollars) of the company Turnstone Biologics (TSBX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing next-generation oncolytic viruses and vaccines for cancer treatment. Its valuation is based on the potential of its innovative platforms. This chart reflects the market's high valuation of its scientific developments and the prospects of its small but highly qualified team of scientists.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772635355086 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Turnstone Biologics is a clinical-stage biopharmaceutical company developing oncolytic viruses and vaccines for cancer treatment. The chart illustrates the immuno-oncology market assessment. It shows how the market views their innovative approach, which aims to stimulate a patient's immune system to fight tumors.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635355140 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Turnstone Biologics (TSBX)
Turnstone Biologics is a clinical-stage biotech company developing two classes of cancer immunotherapies: oncolytic viruses (which kill cancer) and T-cell therapies. This is R&D. This chart shows capital burn: the amount the company spends on each scientist working on these cutting-edge technologies.
%20Chart%20Turnstone%20Biologics%20(TSBX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Turnstone-Biologics-TSBX&v=1772635355195 "Company Profit Per Employee (in thousands of dollars) Chart Turnstone Biologics (TSBX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Turnstone Biologics is a clinical-stage biotech company developing two approaches in immuno-oncology: oncolytic viruses and transient infiltrating lymphocyte (TIL) therapy. This loss per employee reflects the high cost of R&D across two complex areas.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772635355264 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Turnstone Biologics (TSBX) is a clinical-stage biotech company specializing in oncolytic viruses and TIL-based therapies (immunotherapy). It's an R&D company and has no profit. This chart shows its capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635355328 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Turnstone Biologics (TSBX)
Turnstone Biologics is a biotech company developing oncolytic viruses and cell therapies for cancer treatment. This graph reflects the early stages of commercialization of its platforms. Growth in revenue per employee will indicate the success of clinical trials and interest from major pharmaceutical companies in its approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Turnstone-Biologics-TSBX&v=1772635355414 "Sales chart per company employee Turnstone Biologics (TSBX)")
Sales per employee in the market segment - Oncology immuno-therapy
Turnstone Biologics (TSBX) is a biotech company developing cancer immunotherapies, including viral immunotherapies and tumor-infiltrating lymphocyte (TIL)-based therapies. This chart shows how productive their R&D team is, measuring revenue (from partnerships) per scientist.
Sales per employee for the market as a whole
Turnstone Biologics (TSBX) is a clinical-stage biotech developing two types of cancer immunotherapies: oncolytic viruses and TIL therapy. The company has no commercial revenue. This chart reflects a typical R&D situation: the research staff generates data and patents, but not operating income.
Short shares by company, segment and market as a whole
Shares shorted by company Turnstone Biologics (TSBX)
Turnstone Biologics is a biotech company developing "oncolytic viruses" (viruses that kill cancer) to treat tumors. The bearish sentiment shown by this chart is a bet that this highly speculative and complex technology will fail to prove effective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Turnstone-Biologics-TSBX&v=1772635355554 "Short Shares Chart for the Company Turnstone Biologics (TSBX)")
Shares shorted by market segment - Oncology immuno-therapy
Turnstone Biologics (TSBX) is at the forefront of oncology, developing tumor-infiltrating lymphocyte (TIL)-based therapies for the treatment of solid tumors. This chart reflects the collective skepticism of investors about the entire immunotherapy sector. The rising price signaled the market's doubts about the imminent commercialization of these complex and expensive treatments.
Shares shorted by the overall market
Turnstone Biologics is developing oncolytic viruses to fight cancer. This is cutting-edge, but still very early technology. This chart reflects the general pessimism. When fear reigns, investors are reluctant to fund fundamental science. They are selling off TSBX shares, fearing the company will run out of cash long before the technology proves effective.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Turnstone Biologics (TSBX)
Turnstone Biologics (TSBX) is developing a new generation of cancer immunotherapy using oncolytic viruses and cell-based therapies (TILs). It's a cutting-edge but risky biotech. This oscillator measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on early trial data or "oversold" (below 30) due to profit-taking.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Turnstone-Biologics-TSBX&v=1772635355616 "RSI 14 indicator chart for the company's stock Turnstone Biologics (TSBX)")
RSI 14 Market Segment - Oncology immuno-therapy
Turnstone is a "biotech" with a "one-two punch" against cancer. They're developing (1) *oncolytic viruses* and (2) *TIL* therapy. The "Oncology immunotherapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is TSBX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Turnstone Biologics (TSBX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TSBX (Turnstone Biologics)
Turnstone Biologics is a biotech company developing oncolytic viruses and cell-based therapies (TILs) to combat solid tumors. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of this early-stage R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TSBX-Turnstone-Biologics&v=1772635355851 "A chart showing analyst consensus forecasts for the expected stock price. TSBX (Turnstone Biologics)")
The difference between the consensus estimate and the actual stock price TSBX (Turnstone Biologics)
Turnstone (TSBX) is a biotech company developing next-generation T-cell therapies (TILs) for the treatment of solid tumors. This chart measures the gap between the current share price and the consensus target price. It shows the potential (and risks) analysts see in their R&D portfolio and their chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TSBX-Turnstone-Biologics&v=1772635355900 "A chart showing the difference between the consensus forecast and the actual stock price. TSBX (Turnstone Biologics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Turnstone Biologics is a biotech company developing a "dual-strike" attack on cancer: "oncolytic viruses" (tumor-killing agents) and "cell therapy" (TILs). This chart shows analysts' overall expectations for the entire "immunotherapy" sector. It reflects whether experts believe in the success of this "combined" R&D platform.
Analysts' consensus forecast for the overall market share price
Turnstone Biologics (TSBX) – "viruses" against cancer. This biotech company develops "oncolytic viruses" (which kill tumors) and cancer "vaccines." This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk R&D platforms in oncology.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Turnstone Biologics
Turnstone Biologics is a clinical-stage biotech developing two approaches to cancer treatment: oncolytic viruses and tumor-infiltrating lymphocyte (TIL)-based therapies. This is a cutting-edge but risky field. This chart is a comprehensive barometer reflecting the market's assessment of the scientific potential of both platforms, the risks of clinical trials, and funding needs.
AKIMA Market Segment Index - Oncology immuno-therapy
Turnstone Biologics (TSBX) is an immuno-oncology company. They are developing two types of cancer weapons: oncolytic viruses (which infect tumors) and cell-based therapies (TILs). This chart compares their composite index to the immunotherapy sector average.
The AKIM Index for the overall market
Turnstone Biologics is a biotech company developing TIL (tumor-infiltrating lymphocyte) therapy for the treatment of solid tumors. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this innovative cell platform.
